FDA says its mifepristone safety study remains under analysis, and a Senate committee report faults the drug’s three sponsors for prescriber oversight.
The Federal Mifepristone Safety Review Is Still Unfinished While Senators Press Its Three Approved Manufacturers on Oversight
by | Sep 9, 2026 | Uncategorized | 0 comments
Recent Comments